Observational studyYonsei medical journal2026
Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis.
Observational study in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSequential therapy with romosozumab followed by denosumab is used in patients with severe osteoporosis, but predictive factors for bone mineral density (BMD) response remain unclear. MATERIALS AND
methodsThis multicenter retrospective observational study included patients who received 12 monthly romosozumab injections followed by denosumab. Linear mixed-effects models were applied for longitudinal BMD analysis. Fracture incidence was assessed as a secondary endpoint. Both univariable and multivariable analyses were performed, and variance inflation factors were evaluated to ensure model reliability.
resultsBaseline BMD, prior osteoporosis treatment, and nutritional status (as reflected by total lymphocyte count) were identified as significant predictors of BMD response. Within the switched group, patients previously treated with bisphosphonates and those previously treated with denosumab showed heterogeneous responses. Eight fractures occurred during follow-up (one in the treatment-naïve group and seven in the switched group), although this difference did not reach statistical significance.
conclusionBaseline skeletal status, prior treatment history, and nutritional or metabolic status may influence the BMD response to sequential romosozumab-denosumab therapy. These findings may help inform more individualized treatment strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.